Tenosynovial Giant Cell Tumors - Pipeline Insight, 2024

This “Tenosynovial Giant Cell Tumors - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tenosynovial Giant Cell Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Tenosynovial Giant Cell Tumors Understanding

Tenosynovial Giant Cell Tumors: Overview

Tenosynovial giant cell tumors are a group of generally benign intra-articular and soft tissue tumors with common histologic features. They can be roughly divided into localized and diffuse types. Localized types include giant cell tumors of tendon sheath and localized pigmented villonodular synovitis, whereas diffuse types encompass conventional pigmented villonodular synovitis and diffuse-type giant cell tumor. Localized tumors are generally indolent, whereas diffuse tumors are locally aggressive. Recent developments indicate that tenosynovial giant cell tumors are clonal neoplastic tumors driven by overexpression of CSF1. TSGCT is a benign tumor that arises from the tendon sheath in most cases. However, in a few cases, the diffuse type has been documented to lung metastases. The purpose of this case report was to confirm that TSGCT, localized type, can become malignant, and spread to the lungs.

Tenosynovial Giant Cell Tumors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tenosynovial Giant Cell Tumors pipeline landscape is provided which includes the disease overview and Tenosynovial Giant Cell Tumors treatment guidelines. The assessment part of the report embraces, in depth Tenosynovial Giant Cell Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tenosynovial Giant Cell Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Tenosynovial Giant Cell Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Tenosynovial Giant Cell Tumors.

• In September 2022, the US FDA has granted fast track designation to AMB-05X for the treatment of patients with tenosynovial giant cell tumor (TCGT).

Tenosynovial Giant Cell Tumors Emerging Drugs Chapters

This segment of the Tenosynovial Giant Cell Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tenosynovial Giant Cell Tumors Emerging Drugs

Vimseltinib: Deciphera Pharmaceuticals Vimseltinib is an investigational, orally administered, potent and highly selective switch-control kinase inhibitor of CSF1R. Vimseltinib was discovered using our proprietary drug discovery platform and was designed to selectively bind to the CSF1R switch pocket. Vimseltinib has demonstrated encouraging preliminary efficacy and safety data in patients with TGCT. It is currently being evaluated in Phase III clinical trial to treat patients with Tenosynovial Giant Cell Tumors. The MOTION Phase III study is two-part, randomized, double-blind, placebo-controlled study of vimseltinib to assess the efficacy and safety in patients with symptomatic TGCT who are not amenable to surgery.

EI-1071: Elixiron Immunotherapeutics EI-1071 is a small-molecule drug that inhibits the tyrosine kinase activity of the Colony Stimulating Factor-1 Receptor (CSF-1R). EI-1071 has a potentially best-in-class therapeutic index or potency-versus-toxicity profile, shows efficient blood-brain-barrier penetration and causes robust reduction of brain microglia in pre-clinical models. EI-1071 also reduces tumor-associated macrophage numbers and improves tumor control in cancer models. EI-1071 is being developed for the treatment of recurrent and/or diffuse Tenosynovial Giant Cell Tumors (TGCT), a debilitating disease of the joints driven by over-expression of CSF-1, for which a phase II trial is being planned to start in2023.

Tenosynovial Giant Cell Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Tenosynovial Giant Cell Tumors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Tenosynovial Giant Cell Tumors

There are approx. 5+ key companies which are developing the therapies for Tenosynovial Giant Cell Tumors. The companies which have their Tenosynovial Giant Cell Tumors drug candidates in the most advanced stage, i.e. phase III include, DecipheraPharmaceuticals.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Tenosynovial Giant Cell Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tenosynovial Giant Cell Tumors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tenosynovial Giant Cell Tumors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tenosynovial Giant Cell Tumors drugs.

Tenosynovial Giant Cell Tumors Report Insights

• Tenosynovial Giant Cell Tumors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tenosynovial Giant Cell Tumors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tenosynovial Giant Cell Tumors drugs?
• How many Tenosynovial Giant Cell Tumors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tenosynovial Giant Cell Tumors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tenosynovial Giant Cell Tumors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tenosynovial Giant Cell Tumors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AmMax Bio, Inc.
• Deciphera Pharmaceuticals
• SynOx Therapeutics
• Abbisko Therapeutics Co, Ltd.
• Hutchison Medipharma Limited
• Elixiron Immunotherapeutics

Key Products

• AMB-05X
• DCC-3014
• Emactuzumab
• ABSK021
• HMPL-653
• EI-1071

This product will be delivered within 1-3 business days.